Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor
- 16 July 2003
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 100 (16) , 9512-9517
- https://doi.org/10.1073/pnas.1533185100
Abstract
Existing evidence indicates that, in addition to its neuroendocrine action, growth hormone-releasing hormone (GHRH) acts directly on several nonpituitary tissues, especially neoplasms, and stimulates cell proliferation. We have recently reported that a splice variant of the receptor (SV1) is expressed in various normal tissues and particularly in tumor tissues, producing mitogenic effects on GHRH binding. By using HEC-1A human endometrial carcinoma cells, which express endogenous SV1, we show that, in addition to its ability to mediate the mitogenic effects of GHRH, SV1 also possesses relatively high intrinsic, ligand-independent activity. By using an antisense RNA-based approach we found that SV1 ablation reduces the efficacy of colony formation and the rate of cell proliferation of HEC-1A cells in the absence of exogenous GHRH, and decreases their sensitivity to GHRH when the neurohormone is added to the culture media. This ligand-independent stimulation of cell proliferation appears to be a characteristic property of the truncated form of the receptor, because the expression of SV1 and not of the full-length GHRH receptor stimulated the proliferation of 3T3 fibroblasts in the absence of exogenous GHRH, whereas both forms mediated the proliferative effects of GHRH. Evaluation of 21 specimens of human primary endometrial carcinoma for expression of SV1 by immunohistochemistry indicated that in contrast to the GHRH receptor, which is absent, SV1 is expressed in approximately 43% of the specimens. These findings indicate that SV1 can operate in a ligand-independent as well as a ligand-dependent manner. The overexpression of this form of GHRH receptor may be associated with carcinogenesis.Keywords
This publication has 47 references indexed in Scilit:
- Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK‐ES‐1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone‐releasing hormoneCancer, 2002
- Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: Lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factorThe Prostate, 2002
- Localization and Regulation of a Functional GHRH Receptor in the Rat Renal MedullaEndocrinology, 2002
- Antagonists of Growth Hormone-Releasing Hormone and Somatostatin Analog RC-160 Inhibit the Growth of the OV-1063 Human Epithelial Ovarian Cancer Cell Line Xenografted into Nude MiceJournal of Clinical Endocrinology & Metabolism, 2001
- The Origin and Function of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)/Glucagon SuperfamilyEndocrine Reviews, 2000
- CCK receptor polymorphisms: an illustration of emerging themes in pharmacogenomicsTrends in Pharmacological Sciences, 2000
- Expression of Growth Hormone-Releasing Hormone (GHRH) Messenger Ribonucleic Acid and the Presence of Biologically Active GHRH in Human Breast, Endometrial, and Ovarian CancersJournal of Clinical Endocrinology & Metabolism, 1999
- A Tumor-Specific Truncated Estrogen Receptor Splice Variant Enhances Estrogen-Stimulated Gene ExpressionMolecular Endocrinology, 1998
- The Growth-Hormone-Releasing Hormone Receptor: Signal Transduction, Gene Expression, and Physiological Function in Growth RegulationaAnnals of the New York Academy of Sciences, 1996
- Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormoneMolecular Endocrinology, 1993